Brandon Shank, PharmD, MPH, BCOP, discusses the role of the oncology pharmacist in providing consultation and maintaining communication with cancer patients during treatment.
Specialty Pharmacy
Advertisement
Partner violence negatively impacts the ability of women with HIV to adhere to antiretrovirals.
Advertisement
Top news of the day from across the health care landscape.
Patients with chronic obstructive pulmonary disease often have difficulty adhering to medications, which can lead to hospitalization.
Rebecca Shanahan, JD, chief executive officer of Avella Specialty and president of the National Association of Specialty Pharmacy discusses how legislation can impact direct and indirect remuneration fees.
National Association of Specialty Pharmacy states that direct and indirect remuneration fees increase drug costs for seniors.
Advertisement
Bruce A. Feinberg, DO, Vice President and Chief Medical Officer of Cardinal Health Specialty Solutions, discusses the importance of specialty pharmacists in a patient-centric environment.
Heplisav-B aims to boost a patient’s own immune response to fight off HBV.
Two mutations may cause angioimmunoblastic T cell lymphoma.
Top news of the day from across the health care landscape.
Advertisement
The study is the first to evaluate VRC01 antibody in patients who started antiretroviral therapy during acute HIV infection.
Pharmacist intervention on drug-related problems in HIV outpatients can alleviate adherence issues.
Maviret is an 8-week treatment that combines 2 distinct antiviral agents.
Rebecca Shanahan, JD, chief executive officer of Avella Specialty and president of the National Association of Specialty Pharmacy speaks about DIR fees in a 3-part interview.
Top news of the week from Specialty Pharmacy Times.
If approved, Xeljanz will be the first Janus kinase inhibitor for psoriatic arthritis.
Pilot project to bring pre-exposure prophylaxis to the Philippines for the first time.
A look at last week's top stories in the world of pharmacy.
Top news of the day from across the health care landscape.
Durvalumab is indicated to treat patients with locally-advanced, unresectable non-small cell lung cancer.
Targeting cell mutations could disrupt tumor cell growth without harming non-cancerous cells.
With a shift from intravenous to self-administered medication, specialty pharmacists are key in patient education.
Combination therapy cuts standard HCV treatment regimen from 12 weeks to 8 weeks.
Mike Agostino, RPh, president at Amber Pharmacy, president-elect at NASP, talks about the exciting things for this year's NASP Annual Meeting, including keynote speaker, Alex Azar, former president at Eli Lilly.
Rebecca Shanahan, JD, chief executive officer of Avella Specialty and president of the National Association of Specialty Pharmacy speaks out on direct and indirect remuneration fees in a 3-part interview.
An approval decision for Alecensa is expected by November 30, 2017.
Sirukumab is designed to treat adults with moderately-to-severely active rheumatoid arthritis.
Research advances hunt for a safe and effective preventative HIV vaccine.
Vyxeos is indicated to treat newly diagnosed therapy-related AML or AML with myelodysplasia-related changes.
Three weeks of radiation post-mastectomy observed to be safe and effective for breast cancer patients.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
2
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5
